Share This Page
Details for Patent: 9,320,862
✉ Email this page to a colleague
Summary for Patent: 9,320,862
| Title: | Fluid dispensing device | |||||||||||||||||||||||||||||||||
| Abstract: | A fluid dispensing device for dispensing a fluid form medicament formulation having a viscosity of from 10 to 2000 mPa·s, is disclosed having a housing and a fluid discharge device. The fluid discharge device is arranged to be actuated by one or more levers, so as to apply a force to the fluid discharge device which is used to move a container forming part of the fluid discharge device, along a longitudinal axis of the fluid discharge device to cause actuation of a pump forming. A pre-load mechanism prevents actuation of the pump until a pre-determined force is applied to each lever of sufficient magnitude to guarantee the production of a well-developed, efficient spray from the fluid dispensing device. | |||||||||||||||||||||||||||||||||
| Inventor(s): | Michael Birsha Davies, Mark Graham Hedley, James William Godfrey | |||||||||||||||||||||||||||||||||
| Assignee: | Glaxo Group Ltd | |||||||||||||||||||||||||||||||||
| Application Number: | US14/303,773 | |||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Formulation; Device; | |||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | Scope and Claims Analysis of US Patent 9,320,862: Finger-Operable Lever Actuators with Two-Stage “Pre-Load” Profiles for Metered Fluid Medicament Discharge US Patent 9,320,862 is directed to an actuator geometry for fluid dispensing devices that move a discharge component longitudinally only after a threshold force is reached. The core claim theme is a two-stage force-transmission surface with an initial concave, high-gradient region followed by a subsequent convex, lower-gradient region, configured so that “no significant force is transferable” longitudinally until a pre-determined input force is applied. Dependent claims narrow the profile continuity, arc geometry, and placement (one end, upper end), and further require a lever that pivots about a lower end. Combination claims add a housing that constrains transverse actuator motion relative to the device’s longitudinal axis, and specify where the follower is located (container or fitting, including a collar connected to a neck of the container). What is US Patent 9,320,862 protecting and how broad are the independent claims?Direct answer: Claim 1 protects a finger-operable actuating member for a fluid dispensing device that converts transverse finger force into longitudinal movement of a fluid discharge device, using a two-stage actuator-contact profile that creates a pre-load/threshold before significant longitudinal force is transmitted. Claim 1 elements (scope map)Claim 1 can be parsed into six functional/structural elements:
Breadth and likely infringement posture
Internal redundancy in the provided claim setThe list includes duplicates that appear to correspond to the same dependency structure:
How do the dependent claims narrow the scope (profile continuity, arc form, and placement)?Direct answer: The dependent claims narrow Claim 1 by requiring: (i) a smooth breakpoint between curvature stages, (ii) both stages being part-circles, and (iii) the two-stage profile being located at one end or upper end of the lever. Claim 2: Smooth break point between concave and convex sections
Claim 3: Both profiles have part-circle form
Claims 4 and 12: Profile disposed at one end of the actuating member
Claims 7 and 15: Profile disposed at upper end of the lever
Claims 11: “Both have a part-circle form” (duplicate)
Design-around implication: The broadest risk remains for devices using an actuator-contact surface that has (a) threshold/no-transmission behavior, (b) concave-then-convex curvature, and (c) a continuous transition. The narrowest risk is when the competitor uses non-arc curvature, discontinuous breakpoints, or places the threshold geometry at a location other than the claimed ends. What claim language requires “pre-load” and how might courts interpret it?Direct answer: Claim 1 uses pre-load through a structural geometry-to-function coupling: the two-stage profile provides pre-load to prevent discharge until a pre-determined force is applied, with “no significant force transferable” longitudinally until threshold. Key interpretive anchors
These phrases can be treated as functional limitations that still rely on the stated structural geometry (concave high gradient then convex lower gradient). If litigation arises, a patentee’s strongest position is that the geometry is not merely describing a result; it is defining how the force transmission is controlled. Practical engineering mapping
Which embodiments are explicitly required: lever geometry and transverse pivotal actuation?Direct answer: Dependent claims explicitly lock in a lever with pivot about a lower end and a two-stage profile at the upper end (Claims 5–7 and 13–15). Claims 5–7 (and the repeated chain 13–15)
This structure is narrower than a generic “actuating member” and is likely the primary target for molded plastic actuator designs or hinged actuator mechanisms. Design-around implication: Devices using a sliding button, rotating cam, flexible diaphragm, or magnetically actuated system may avoid these dependent limitations, but could still fall under Claim 1 if they still use a two-stage concave-then-convex threshold contact surface for force transmission. What combination claims add a housing and a container/fitting follower?Direct answer: Claims 8 and 16 add a housing that movably houses the discharge component and constrains transverse actuator motion. Claims 9–10 and 17–18 specify the follower location and, in one dependent branch, the follower is in a fitting comprising a collar connected to a neck of the container. Housing limitation (Claims 8 and 16)
This narrows to integrated dispenser architectures where the actuator is constrained within a housing rather than an externally applied force path. Follower location (Claims 9–10 and 17–18)
Commercial relevance: Many prefilled medicament systems use neck-and-collar interfaces or adapter collars. This limitation can be used to argue coverage for specific mechanical integration patterns. How many claim variations exist in the provided set, and what does that suggest for claim coverage?Direct answer: The provided list contains an independent Claim 1 and a cluster of dependent claims (2–18) focusing on:
Coverage matrix (based on provided claims only)
Net: Claim 1 provides the broadest geometry-to-function coverage; the dependent claims tighten to specific mechanical implementations. What is the likely technical “inventive concept” behind 9,320,862?Direct answer: The inventive concept is a two-stage contact surface on a manually actuated member that creates a threshold (pre-load) behavior preventing premature longitudinal actuation and discharge. Why the curvature order mattersClaim 1 specifies:
A competitor that swaps concave/convex order or uses a single smooth monotonic curvature without a two-stage gradient change can argue the absence of the “two-stage profile comprises” limitation. A competitor that uses two-stage behavior but with different curvature definitions may contest whether “concave high gradient” and “convex lower gradient” read on its design. Patent landscape: what other patents typically surround this type of dispenser actuator?Direct answer: This patent sits in a crowded device-adjacent space where most surrounding patents claim one or more of: (i) actuator geometry/threshold force mechanisms, (ii) prefilled medicament dispensing architectures with followers, (iii) lever or button actuation mechanisms, and (iv) container-neck/collar interfaces. However, the request is specifically for “Detailed analysis of the scope and claims and patent landscape for United States Drug Patent 9,320,862,” and the only concrete data provided here is the claim set. Without the application data, assignee, prosecution history, cited references, and (critically) the Orange Book or FDA device/drug association, a complete landscape mapping (other family members, continuations, litigations, or generic/biosimilar risk) cannot be produced accurately. Per constraints, no additional landscape assertions are included. How might this patent affect generic or competitor entry?Direct answer: For products using a fluid dispensing medicament device, the main legal threat is not “generic drug substitution” but mechanical and method substitution risk: copying the actuator’s two-stage threshold force-transmission geometry, even if the medicament formulation is different.
When does exclusivity end and what is the enforcement timeline?Direct answer: The provided prompt does not include filing date, priority date, patent term adjustments, or terminal disclaimer terms for US 9,320,862, so a correct end-of-exclusivity timetable cannot be stated. Key Takeaways
FAQs1) What actuator designs are closest to US 9,320,862’s Claim 1? 2) Does Claim 1 require a lever, or can the actuator be other shapes? 3) What does “two-stage profile” mean legally in Claim 1? 4) How can a competitor design around the “pre-load means” aspect? 5) Are the collar/neck and housing limitations necessary for all infringement? References (APA)No sources were cited because no bibliographic or evidentiary material beyond the provided claim text was included. More… ↓ |
Drugs Protected by US Patent 9,320,862
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,320,862
International Family Members for US Patent 9,320,862
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 534589 | ⤷ Start Trial | |||
| Australia | 2004287261 | ⤷ Start Trial | |||
| Australia | 2005221876 | ⤷ Start Trial | |||
| Australia | 2010201953 | ⤷ Start Trial | |||
| Australia | 2010246483 | ⤷ Start Trial | |||
| Brazil | PI0416128 | ⤷ Start Trial | |||
| Brazil | PI0508586 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
